Kestra Advisory Services’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.04M Buy
164,361
+17,511
+12% +$830K 0.02% 697
2025
Q4
$7.47M Buy
146,850
+38,598
+36% +$1.97M 0.03% 530
2025
Q3
$6.01M Sell
108,252
-18,444
-15% -$1.08M 0.03% 590
2025
Q2
$8.74M Sell
126,696
-29,834
-19% -$2.03M 0.04% 422
2025
Q1
$10.9M Buy
156,530
+17,562
+13% +$1.45M 0.05% 326
2024
Q4
$12M Buy
138,968
+13,739
+11% +$1.49M 0.07% 307
2024
Q3
$14.9M Sell
125,229
-19,866
-14% -$2.65M 0.08% 260
2024
Q2
$19.3M Buy
145,095
+20,479
+16% +$2.71M 0.11% 202
2024
Q1
$16M Buy
124,616
+23,641
+23% +$2.81M 0.11% 190
2023
Q4
$10.4M Buy
100,975
+20,792
+26% +$2.06M 0.08% 262
2023
Q3
$7.29M Buy
80,183
+29,823
+59% +$2.63M 0.07% 292
2023
Q2
$4.07M Buy
50,360
+4,132
+9% +$338K 0.04% 433
2023
Q1
$3.68M Sell
46,228
-49,230
-52% -$3.49M 0.04% 445
2022
Q4
$6.46M Buy
95,458
+10,478
+12% +$614K 0.06% 347
2022
Q3
$4.23M Buy
84,980
+5,656
+7% +$303K 0.05% 418
2022
Q2
$4.42M Buy
79,324
+35,124
+79% +$1.95M 0.05% 392
2022
Q1
$2.45M Buy
44,200
+6,278
+17% +$322K 0.03% 604
2021
Q4
$2.12M Sell
37,922
-7,674
-17% -$416K 0.02% 655
2021
Q3
$2.19M Buy
45,596
+6,550
+17% +$317K 0.02% 669
2021
Q2
$1.64M Buy
39,046
+278
+0.7% +$10.8K 0.02% 729
2021
Q1
$1.31M Buy
38,768
+16,706
+76% +$595K 0.02% 762
2020
Q4
$774K Buy
22,062
+21,900
+13,519% +$757K 0.01% 989
2020
Q3
$372K Buy
+162
New +$5.4K 0.01% 1007

Other funds holding NVO

Kestra Advisory Services's NVO Position: Q1 2026 in Review

Kestra Advisory Services increased its Novo Nordisk (NVO) stake by 12% in Q1 2026, buying an estimated $830K and bringing the position to 164,361 shares worth $6.04M. The position accounts for 0.02% of the portfolio, ranked #697.

Kestra Advisory Services first reported a position in NVO in Q3 2020 and has held it in 23 quarters since. The position peaked at $19.3M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Kestra Advisory Services held 164,361 shares of Novo Nordisk worth $6.04M as of Q1 2026.
  • Kestra Advisory Services bought 17,511 Novo Nordisk shares in Q1 2026, an estimated $830K.
  • Novo Nordisk made up 0.02% of Kestra Advisory Services's portfolio in Q1 2026, its #697 holding.
  • Kestra Advisory Services first reported a position in Novo Nordisk in Q3 2020 and has held it in 23 quarters since.
  • Kestra Advisory Services's Novo Nordisk position peaked at $19.3M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.